Cytomedix New: (OTCBB: CMXI)
$0.51
0.05 (10.87%)
Volume 87,280
May 21 03:59 PM ET
Zacks Rank: 3-Hold 
| #3 |
Overview Quote
Stock Activity
| Day Low - High | 0.46 - 0.52 |
| 52wk Low - High | 0.43 - 2.32 |
| Previous Close | 0.46 |
| Avg. Volume | 92,610 |
| Industry | MED-BIOMED/GENE |
| Market Cap | 47.99 M |
| Div - Yield | 0.00 - 0.00 |
| Beta | 0.26 |
| PE (Forward) | 0.00 |
| Current Year Est. | -0.14 |
| Quarterly Earnings ESP |
NA |
Premium research
Zacks Rank
|
3 |
Zacks Recommendation
|
NA |
Zacks Industry Rank
|
91 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | NA |
| PEG Ratio | NA |
| Current Year Est. | -0.14 |
| Current Quarter Estimate | -0.03 |
| Most Accurate Estimate | NA |
| Earnings ESP |
NA |
| Next Earnings Report Date | 05-09-2013 |
| EPS Last Year | -0.09 |
| Expected Earnings Growth | NA |
Company Description
Cytomedix, Inc. is a biotechnology company specializing in the research, development, licensing, and distribution of systems for autologous cellular therapies. Currently, the Company sells its proprietary and patented AutoloGel process to the health care market for the treatment of chronic wounds. Cytomedix has national contracts with long-term care providers and home health companies to provide its AutoloGel process to treat residents and patients with non-healing wounds, especially pressure ulcers.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (ND) |
Next Qtr (ND) |
Current Year (ND) |
Next Year (ND) |
|
|---|---|---|---|---|
| Average Estimate | NA | NA | NA | NA |
| Number of Estimates | NA | NA | NA | NA |
| Low Estimate | NA | NA | NA | NA |
| High Estimate | NA | NA | NA | NA |
| Year Ago EPS | NA | NA | NA | NA |
| EPS Growth | NA | NA | NA | NA |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| CYTOMEDIX INC | CMXI | 0.46 | |
|
| AETERNA ZENTARS | AEZS | 2.06 | |
|
| ANIKA THERAPEUT | ANIK | 14.39 | |
|
| GENTIUM SPA-ADR | GENT | 8.84 | |
|
| AASTROM BIOSCI | ASTM | 0.59 | |
|
| ACHILLION PHARM | ACHN | 7.55 | |
|
| ADDEX THERA LTD | ADDXF | 6.94 | |
|
| AFFYMAX INC | AFFY | 1.27 | |
|
| ALEXION PHARMA | ALXN | 100.03 | |
|
| ALKERMES INC | ALKS | 31.04 | |
|
Sector:Medical>> Industry:MED-BIOMED/GENE
COMPARE TICKER vs. Its Peers
Zacks Commentary
Financials
| EPS TTM | -0.09 |
| Sales | 11 |
| Net Income | -20 |
| Price/Earnings | NA |
| Price/Book | 1.11 |
| Price/Cash Flow | NA |
| Price/Sales | 4.55 |
News
Cytomedix to Present at the World Stem Cells & Regenerative MedicineCongress 2013 - Marketwire
May 17, 2013
WEALTHMAKERS.COM Issues Bullish Research Reports on CMXI, DHR, ETAK, EXAR, HSTM, HTLF - M2
May 17, 2013
Cytomedix, Inc.Corporate Event Announcement Notice - Wall Street Horizon
May 10, 2013
WEALTHMAKERS.COM Issues Bullish Research Reports on AEH, ARNA, AXFN, CMXI, CNTY, EGN - M2
May 10, 2013
Cytomedix Reports First Quarter 2013 Financial Results - Marketwire
May 9, 2013
Cytomedix, Inc.Corporate Event Announcement Notice - Wall Street Horizon
May 9, 2013
Cytomedix, Inc.Corporate Event Announcement Notice - Wall Street Horizon
May 7, 2013
Cytomedix to Host First Quarter 2013 Financial Results ConferenceCall on Friday, May 10, 2013 - Marketwire
May 6, 2013
Broker Recommendations
| Current ABR | 3.00 |
| ABR (Last Week) | 3.00 |
| # of recs in ABR | 1 |
| Average Target Price | 1.50 |
| Industry Rank by ABR | 91 out of 265 |
| Rank in Industry | 38 out of 156 |
